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A B S T R A C T
The naphthoquinone buparvaquone is currently the only drug used against theileriosis. Here, the effects
of buparvaquone were investigated in vitro and in an experimental mouse model for Neospora caninum
infection. In 4-day proliferation assays, buparvaquone eﬃciently inhibited N. caninum tachyzoite repli-
cation (IC50 = 4.9 nM; IC100 = 100 nM). However, in the long term tachyzoites adapted and resumed
proliferation in the presence of 100 nM buparvaquone after 20 days of cultivation. Parasiticidal activity
was noted after 9 days of culture in 0.5 μM or 6 days in 1 μM buparvaquone. TEM of N. caninum in-
fected ﬁbroblasts treated with 1 μM buparvaquone showed that the drug acted rather slowly, and
ultrastructural changes were evident only after 3–5 days of treatment, including severe alterations in
the parasite cytoplasm, changes in the composition of the parasitophorous vacuole matrix and a dimin-
ished integrity of the vacuole membrane. Treatment of N. caninum infected mice with buparvaquone
(100 mg/kg) either by intraperitoneal injection or gavage prevented neosporosis symptoms in 4 out of
6 mice in the intraperitoneally treated group, and in 6 out of 7 mice in the group receiving oral treat-
ment. In the corresponding controls, all 6 mice injected intraperitoneally with corn oil alone died of acute
neosporosis, and 4 out of 6 mice died in the orally treated control group. Assessment of infection inten-
sities in the treatment groups showed that, compared to the drug treated groups, the controls showed
a signiﬁcantly higher parasite load in the lungs while cerebral parasite loadwas higher in the buparvaquone-
treated groups. Thus, although buparvaquone did not eliminate the parasites infecting the CNS, the drug
represents an interesting lead with the potential to eliminate, or at least diminish, fetal infection during
pregnancy.
© 2015 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
1. Introduction
Apicomplexan parasites are responsible for a variety of dis-
eases in humans, pets and/or farm animals, and are thus of high
medical and economic importance. Those most relevant for farm
animals are Babesia, Besnoitia, Cryptosporidium, Eimeria, Neospora,
Sarcocystis, Theileria, and Toxoplasma, all causing diseases of great
socio-economic impact worldwide (Müller and Hemphill, 2013).
Neospora caninum is phylogenetically closely related to Toxo-
plasma gondii, but distinct from Toxoplasma with regard to several
biological features including the life cycle, host range and patho-
genicity (Hemphill et al., 2006, 2013). Canids, namely dogs, wolves,
dingoes and coyotes, represent deﬁnitive hosts of N. caninum. Besides
cattle, sheep, goats, and many more species have been reported as
intermediate hosts (Buxton et al., 2002; Dubey, 2003). Three infec-
tive stages of N. caninum have been identiﬁed to date. These are (i)
tachyzoites, which represent the disease-causing and rapidly pro-
liferating stage; (ii) slowly replicating bradyzoites that form tissue
cysts; and (iii) sporozoites, the end products of a sexual process,
which takes place in the intestine of the deﬁnitive host followed
by sporulation in the environment. Although a sylvatic cycle for
N. caninum has been demonstrated (Rosypal and Lindsay, 2005;
Gondim, 2006), its importance as reservoir for the transmission to
domestic animals has not been deﬁnitely elucidated.
Infection of pregnant cattle with N. caninum causes annual losses
of around 1.3 billion US dollars through abortion, stillbirth, or birth
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of weak offspring (Reichel et al., 2012). In addition, N. caninum in-
fection can result in birth of clinically healthy, but persistently
infected calves, which in turn then vertically transmit the parasite
to the next generation. Control options to limit the economic impact
of neosporosis that have been proposed and modeled include (i)
testing and culling of seropositive animals, (ii) discontinued breed-
ing with offspring from seropositive cows, (iii) vaccination of
susceptible and infected animals, and (iv) chemotherapeutic treat-
ment of calves from seropositive cows (Häsler et al., 2006a, 2006b).
However, the most effective option is not always the most econom-
ic one and a detailed economic study has to be made speciﬁcally
for each case before deciding on a control strategy (Larson et al.,
2004; Häsler et al., 2006a; Reichel and Ellis, 2006). In addition, none
of the control strategies studied to date have reached a
seroprevalence of zero because of the existence of the horizontal
transmission. In order to eliminate N. caninum, it would be neces-
sary to control both the vertical transmission within a herd as well
as the horizontal transmission through oocyst shedding by
canids (Häsler et al., 2008). In this context, treatment options for
dogs would also represent an interesting aspect (Monney and
Hemphill, 2014).
In general, chemotherapeutic treatment of seropositive animals
has not been regarded as economically interesting, since to date no
effective and safe drugs are available on the market, and because
of the long period of treatment during which milk or meat from
drug treated animals remains unacceptable (Dubey et al., 2007). Nev-
ertheless, experimental studies have revealed potentially interesting
effects of several compounds in vitro and in laboratory animalmodels
in vivo (Müller and Hemphill, 2011). Other publications reported
on further promising drug candidates including toltrazurilsulfone
(ponazuril) (Kritzner et al., 2002; Strohbusch et al., 2009), artemisone
(Mazuz et al., 2012), di-cationic diamidine derivatives (Debache et al.,
2011; Schorer et al., 2012), miltefosine (Debache and Hemphill,
2012), organometallic ruthenium complexes (Barna et al., 2013) and
bumped kinase inhibitors (Ojo et al., 2014).
Buparvaquone (2-((4-tert-butylcyclohexyl)methyl)-3-hydroxy-
1,4-naphthoquinone; BPQ) is a hydroxynaphthoquinone related to
parvaquone. Developed in the 1980s, BPQ has been extensively tested
for veterinary use against Theileria annulata (Tropical theileriosis),
Theileria parva (East Coast Fever) (McHardy et al., 1985; Dhar et al.,
1986;Wilkie et al., 1998) and Theileria sergenti (Minami et al., 1985),
both in laboratory studies and in ﬁeld trials. BPQ kills T. parva in vitro
with an IC50 of 10 nM (McHardy et al., 1985), and 150 nM of BPQ
are suﬃcient to induce parasiticidal activity in Theileria-infected
bovine macrophage cell lines (Hostettler et al., 2014). Moreover, ac-
tivities of BPQ against a number of infectious diseases other than
theileriosis have been described, including malaria (Martin et al.,
1973), cryptosporidiosis (Kayser et al., 2001), leishmaniasis (Croft
et al., 1992), and Pneumocystis carinii pneumonia in AIDS and im-
munosuppressed patients (Kaneshiro et al., 2001). The mechanism
of action of the drug has not been fully elucidated. In analogy to
atovaquone and other 1,4-naphthoquinones, BPQ most likely acts
via a mechanism involving the inhibition of Complex III (b-c1
complex) as postulated to be the case in Theileria, Plasmodium,
Eimeria and Toxoplasma (Hudson et al., 1985; Fry and Pudney, 1992).
In the particular case of P. carinii there seems to be more than one
mechanism of action of the drug. The effect of BPQ and other
naphthoquinones on the ubiquinone (Q10) biosynthesis has also been
described (Kaneshiro et al., 2001, 2006).
In the case of neosporosis, with no vaccine and no drug cur-
rently on themarket, drug repurposing could be a valuable approach
to identify compounds that limit the effects of the disease, and these
could be rather rapidly implemented. BPQ represents an obvious
candidate, as this compound is already used in cattle. In this study,
we report the inhibitory effects of BPQ treatment of N. caninum in
vitro and in an experimental mouse infection model.
2. Materials and methods
2.1. Tissue culture media, biochemicals, and drugs
If not otherwise stated, all tissue culture media were pur-
chased from Gibco-BRL (Zürich, Switzerland), and biochemical
reagents were from Sigma (St. Louis, MO). Kits for molecular biology
were purchased from Qiagen (Hilden, Germany). Buparvaquone
(McHardy and Morgan, 1985) was provided by Cross Vetpharm
Group Limited (Dublin, Ireland), and was kept as 1.5 mM stock so-
lution in dimethyl sulfoxide (DMSO) at −20 °C.
2.2. Host cell cultivation and parasite cultures
Human foreskin ﬁbroblasts (HFF) were maintained in Dulbecco’s
Modiﬁed Eagle Medium (DMEM), and Vero cells were cultured in
RPMI-1640 medium, both with phenol red supplemented with 10%
heat inactivated and sterile ﬁltrated fetal calf serum (FCS), 50 U of
penicillin/ml, and 50 μg streptomycin/ml (=culture medium). They
were cultured at 37 °C and 5% CO2 in tissue culture ﬂasks (Sarstedt,
Sevelen, Switzerland). Cultures were passaged at least once a week.
Transgenic beta-galactosidase expressing-N. caninum (Nc-beta-
gal) tachyzoites (used for screening purposes) and the N. caninum
Liverpool (Nc-Liv) isolate weremaintained by serial passages in Vero
cells in the same medium (Schorer et al., 2012; Barna et al., 2013).
Tachyzoites were harvested by scraping off the infected cell layer
with a rubber cell scraper, followed by repeated passages through
a 25-gauge needle at 4 °C, and separation from cell debris on a
Sephadex-G25 column (Hemphill et al., 1996). Puriﬁed tachyzoites
were used to infect HFF monolayers or for in vivo experiments as
described below.
2.3. Alamar blue cytotoxicity assay
Viability assessment of HFF upon drug exposure was done as pre-
viously reported (Küster et al., 2012). Flat bottomed 96 well plates
(Gibco-BRL) were seeded with 1 × 103 HFF per well in phenol-red
free culture medium and grown at 37 °C and 5% CO2 to conﬂuence
before adding BPQ or DMSO as a solvent control. The cells were
further cultured at 37 °C and 5% CO2 for 5 days. Subsequently,
mediumwas removed and 0.2 ml PBS containing resazurin (10mg/
ml) were added per well, and the ﬂuorescence at 590 nmwavelength
(FI590) was measured at various time points using an Enspire
multilabel counter (2300 EnSpire™ Multilabel Reader, Perkin-
Elmer, Turku, Finland).
2.4. Measurement of the toxicity of BPQ against
N. caninum tachyzoites
Assays based on a transgenic N. caninum strain expressing beta-
galactosidase (Nc-beta-gal) were used (Barna et al., 2013). Flat
bottomed 96 well plates (Sarstedt) were seeded with 5 × 103 HFF
cells per well in culture medium and cultured at 37 °C and 5% CO2
until they had grown to conﬂuence. Prior to the drug treatment, the
old mediumwas removed and 100 μl of fresh culture medium con-
taining 1 × 103 freshly harvested N. caninum Nc-beta-gal tachyzoites
were distributed per well. Immediately thereafter, BPQ was added
at desired amounts in 100 μl culture medium. Negative controls re-
ceived the corresponding amounts of DMSO. The cultures were
further maintained at 37 °C and 5% CO2. After 96 h, the plates were
centrifuged at 500 rpm for 5min, mediumwas removed, and 200 μl
PBS was added to each well. After a second centrifugation (500 rpm,
5 min), PBS was removed and 100 μl PBS containing 0.05% Triton
X-100 and 0.5 mM chlorophenol red-beta-D-galactopyranoside
(CPRG; Roche Diagnostics, Rotkreuz, Switzerland) was added. CPRG
was hydrolyzed by beta-galactosidase, causing the release of
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chlorophenol red, which was measured at (A570) at various time
points in a VersaMax 96well multiplate reader (Bucher Biotec, Basel,
Switzerland). The initial velocity (ΔA570/min) was proportional to
the number of tachyzoites.
To analyze effects of BPQ on extracellular tachyzoites and its
ability to inhibit host cell invasion, Nc-beta-gal tachyzoites were pu-
riﬁed as described and incubated in medium containing 0.5 μM BPQ
or DMSO as a solvent control for 2 h followed by three washes with
medium (i.e. centrifugation at 2300 × g for 5 min at 4 °C). The pellet
was resuspended in medium and seeded at a density of 5 × 105
tachyzoites per well on conﬂuent HFF layers grown in a 96-well-
plate. After a subsequent incubation at 37 °C for 24 h, the beta-
galactosidase-assay was performed as described.
In order to explore the effects of BPQ with regard to an already
established infection, HFF monolayers were infected as above, and
BPQ (100 nM) was added at the time point of adding the tachyzoites,
after 72 h, or after 90 h of culture. After 96 h, the plates were cen-
trifuged at 200 × g for 5 min, medium was removed, and beta-
galactosidase activity was measured at (A570) as described above.
2.5. Assessment of parasiticidal activities of BPQ
HFF (5 × 105/ﬂask) were inoculated into a T25 tissue culture ﬂask,
and after 2–4 h, ﬁbroblasts were infected with 1 × 106 N. caninum
Nc-Liv tachyzoites. After 1 day, the mediumwas substituted by fresh
culture medium, or medium containing 100 nM, 500 nM, 1 μM or
2.5 μM of BPQ as indicated in Table 1. Drug-containing media were
removed and substituted by normal media without compound on
days 3, 6 or 9. During these time periods, the ﬂasks were micro-
scopically checked on a daily basis for signs of re-emerging parasite
replication and parasitophorous vacuole formation. As soon as
patches of destroyed HFF monolayers appeared as plaques due to
tachyzoite egress, this was considered proof of regrowth and the
experiment was terminated.
2.6. Transmission electron microscopy
HFF (5 × 105/ﬂask) were inoculated into a T25 tissue culture
ﬂask and were infected with 5 × 105 N. caninum (Nc-Liv) tachyzoites.
From 24 h p.i. infection onwards, the cultures were treatedwith 1 μM
BPQ, control cultures were treated with the corresponding amount
of DMSO. After 1, 2 and 5 days of continuous culture in the pres-
ence of BPQ, monolayers were washed with 100 mM sodium
cacodylate buffer (pH 7.3) and ﬁxed with cacodylate buffer con-
taining 2.5% glutaraldehyde for 10 min. Cells were collected using
a rubber cell scraper, centrifuged for 10 min at 1200 rpm at room
temperature, the supernatant was removed, and infected cells were
ﬁxed further in 2.5% glutaraldehyde/cacodylate at 4 °C overnight.
Postﬁxation was carried out in 2% OsO4 in cacodylate buffer for 2 h
at room temperature, followed by extensive washing of the ﬁxed
material in water. After pre-staining in saturated uranyl acetate for
1 h at room temperature, specimens were dehydrated in a graded
series of ethanol (30%, 50%, 70%, 90%, 3 × 100%) and embedded in
Epon 820 epoxy resin, with two resin changes during 48 h. Poly-
merization of the resin was achieved at 65 °C for 24 h. Ultrathin (80
to 90 nm) sections were cut on a Reichert and Jung ultramicro-
tome, sections were loaded onto 300-mesh copper grids (Plano
GmbH), and samples were stained with uranyl acetate and lead
citrate (Kropf et al., 2012). Specimens were viewed on a Phillips 400T
transmission electron microscope operating at 80 kV.
2.7. Effects of BPQ treatment of host cells prior to invasion by
N. caninum tachyzoites
To study whether pretreatment of host cells prior to invasion had
any effect on parasite proliferation, conﬂuent HFF grown in 6-well
plates were treated with 1 μM BPQ in medium for 1 h or 5 h, and
controls were exposed to the corresponding amounts of DMSO. Sub-
sequently, the drug-containing medium was removed and
monolayers were washed 4 times with Hank’s Balanced Salt Solu-
tion, and were infected with 1 × 106Nc-Liv tachyzoites in 5 ml
medium without any drug or solvent. After 2 days, cells were col-
lected with a cell scraper, centrifuged, washed once more in PBS,
and the pellet was stored at −20 °C prior to quantiﬁcation of
N. caninum proliferation by N. caninum-speciﬁc real time PCR as out-
lined below.
2.8. In vivo effects of BPQ in N. caninum infected mice
Twenty ﬁve female Balb/c mice between 8 and 9 weeks of age
were purchased from Charles River Laboratories (Sulzheim, Germany)
and were maintained in a common room under controlled tem-
perature and a 14 h dark/10 h light cycle according to the standards
set up by the animal welfare legislation of the Swiss Veterinary Oﬃce.
The experimental protocol was approved by the Commission for
Animal Experimentation of the Canton of Bern, Switzerland (Animal
license No. BE115/14). Mice were randomly caged into four
experimental groups as outlined in Table 2. Enzyme-linked
immunosorbent assay (ELISA) was carried out to ensure that mice
were serologically Neospora-negative (Debache et al., 2010). On day
0, all mice were infected by intraperitoneal (i.p.) injection of 2 × 106
freshly puriﬁed N. caninum tachyzoites. After 48 h, mice received
BPQ (100 mg/kg) as suspension in corn oil either by i.p. injection
Table 1
Long-term BPQ treatments of N. caninum tachyzoites grown in human ﬁbroblasts.
HFF monolayers cultured in T25 tissue culture ﬂasks were infected with N. caninum
Nc-Liv tachyzoites. Treatments were carried out for 3, 6, or 9 days in the presence
of various concentrations of BPQ. Culture post-treatment took place in the absence
of compounds for a maximum time span of 35 days.
BPQ concentration
(μM)
Duration of
treatment (days)
Culture post-
treatment (days)*
Parasitical effect
(yes/no)
0 No treatment 3 No
0.1 20** n.d. No
0.5 3 3 No
6 10 No
9 35*** Yes
1.0 3 9 No
6 35*** Yes
2.5 3 10 No
6 35*** Yes
* Numbers indicate the numbers of days of culture in the absence of BPQ follow-
ing treatment until re-emergence of parasite proliferation was evident by the
occurrence of plaques detected by light microscopy.
** Parasite proliferation was observed after 20 days continuous culture in the pres-
ence of 0.1 μM BPQ.
*** No reappearence of Neospora after culture in the absence of BPQ, indicating para-
siticidal effect.
Table 2
Effects of BPQ treatments on survival of N. caninum infected mice. On day 0, Balbc
mice were infected by intraperitoneal injection of 2 × 106 freshly puriﬁed N. caninum
Nc-Liv tachyzoites. After 48 h, mice received buparvaquone (BPQ; 100mg/kg) as sus-
pension in corn oil either by intraperitoneal injection of a volume of 100 μl (i.p.),
or orally by application of 100 μl by gavage (or). The control groups obtained the
corresponding amount of the solvent only. The treatments were performed 5 times
on a daily basis.
Group No. of mice Mortalitya Time of death (day p.i.)
BPQ ip 6 2 7/7
Control i.p. 6 6 6/6/7/7/7/7
BPQ p.o 7 1 19b
Control p.o 6 4 7/8/9/9
a Number of mice killed upon severe acute disease signs.
b Euthanized due to neurological signs of disease.
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of a volume of 100 μl or by oral application of 100 μl by gavage. The
control groups obtained the corresponding amount of the solvent
only, either i.p. or orally (see Table 2). The treatments were per-
formed 5 times on a daily basis. If not indicated otherwise, mice
were inspected twice daily for clinical signs (ruﬄed coat, apathy,
hind limb paralysis) until day 21 post infection (p.i.), at which time
they were euthanized. Mice exhibiting clinical signs prior to day 21
p.i. were euthanized earlier. From each animal the brain and pieces
of lung were recovered and processed for DNA-extraction (Debache
et al., 2010; Monney et al., 2011).
2.9. DNA extraction and assessment of cerebral parasite burden by
real time PCR
DNA puriﬁcation from in vitro cultures, brain and lung tissues
was performed employing the DNeasy Blood & Tissue Kit (Qiagen,
Basel, Switzerland) according to the standard protocol suitable for
animal tissues. The DNA concentrations in all samples were deter-
mined using the QuantiFluor dsDNA System (Promega, Madison,WI)
according to the manufacturer’s instructions and adjusted to 5 ng/
μl with sterile DNAse free water. The assessments of N. caninum
tachyzoite loads were performed using the Rotor-Gene 6000 real-
time PCR machine (Corbett Research, Qiagen). The parasite counts
were calculated by interpolation from a standard curve with DNA
equivalents from 1000, 100 and 10 parasites included in each run
(Schorer et al., 2012; Ojo et al., 2014).
2.10. Statistics
IC50 values were calculated after the logit-log-transformation of
the relative growth (RG; control = 1) according to the formula ln[RG/
(1-RG)] = a × ln(drug concentration) + b and subsequent regression
analysis by the corresponding software tool contained in the Excel
software package (Microsoft, Seattle, WA, USA). Survival analysis of
in vivo experiments was done via Kaplan–Meier estimator fol-
lowed by regression analysis according to Cox and by Log-Rank
analysis. Statistical analysis of the parasite burdens in brain and lungs
was done by two-way ANOVA followed by pairwise t-tests with
Bonferroni correction. These analyses were performed using the soft-
ware package R (R Core Team, 2012).
3. Results
3.1. Effects of BPQ treatment on N. caninum proliferation in
human ﬁbroblasts
The effects of BPQ treatment were investigated in 4-day prolif-
eration assays (Fig. 1A). HFF monolayers were infected with
N. caninum tachyzoites expressing beta-galactosidase and BPQ was
added at different concentrations. Measurement of beta-galactosidase
activity showed that BPQ profoundly impaired N. caninum prolif-
eration, with an IC50 (the concentration that inhibited the
proliferation of tachyzoites by 50%) of 4.9 nM (Fig. 1A). Tachyzoite
proliferation was entirely blocked at 100 nM. In contrast, BPQ had
no effect on the viability of HFF monolayers (IC50 > 50 μM; data not
shown).
In a next experiment, we investigated whether BPQ could also
exert anti-parasitic activity in an already established infection
(Fig. 1B). HFF monolayers were infected with N. caninum tachyzoites
and BPQ (100 nM) was added at the time point of infection, or al-
ternatively after 72 h or 90 h of culture. Parasites were harvested
after 96 h p.i. Beta-galactosidase activity measurements con-
ﬁrmed that 100 nMBPQ completely inhibited tachyzoite proliferation
during these 4 days, and a pronounced effect was also noted when
the compound was added after 72 h. Addition of BPQ at 90 h p.i.
Fig. 1. Inhibition of N. caninum proliferation by buparvaquone. (A) HFF were grown
to conﬂuence in a 96-well plate, treated with buparvaquone (BPQ) at various con-
centrations or DMSO as a solvent control and infected with N. caninum tachyzoites
(103 per well) expressing the Escherichia coli beta-galactosidase gene. After 3 days,
beta-galactosidase activity resulting from intracellular tachyzoites was deter-
mined. The activity is given as percentage of the solvent control. Mean values ± SE
correspond to four replicates. (B) HFF were grown to conﬂuence in a 96-well plate,
infected with N. caninum tachyzoites (103 per well) expressing the E. coli beta-
galactosidase gene. After different time points, the infected cells were treated with
100 nM buparvaquone (BPQ) or with DMSO as a solvent control. After 4 days, beta-
galactosidase activity resulting from intracellular tachyzoites was determined. The
activity is given as percentage of the solvent control. Mean values ± SE correspond
to four replicates. The values marked by an asterisk are signiﬁcantly different from
the corresponding control value (two-sided t-test, P < 0.01). (C) HFF grown in 6 well
plates were treated with 1 μM BPQ for 1 or 5 h, washed with PBS, and infected with
2 × 105 N. caninum tachyzoites/well. After 4 days, cells were harvested and sub-
jected to quantitative real time PCR. Results are shown as % proliferation in relation
to untreated controls. Mean values ± SE correspond to four replicates. The values
marked by asterisks are signiﬁcantly different from the corresponding control value
(two-sided t-test, P < 0.01).
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(6 h prior to harvesting of cells) did not have a signiﬁcant effect on
tachyzoite proliferation.
When extracellular tachyzoites were treated with BPQ fol-
lowed by removal of BPQ prior to infection using the experimental
set-up as described, the treatment had no signiﬁcant effects on
further proliferation. After 24 h p.i., the beta-galactosidase activi-
ties (ΔmA570/min) were 5.3 ± 0.2 for BPQ treated tachyzoites vs.
4.6 ± 0.3 for control tachyzoites.
In an additional experiment HFFmonolayers were pretreatedwith
BPQ for 1, 5 and 20 h, respectively, and monolayers were subse-
quently infected with N. caninum tachyzoites in the absence of BPQ
and cultured for a period of 2 days. At the end of the experiment,
assessment of parasite replication by real-time PCR showed that a
1 h pretreatment did not have a pronounced negative impact on
tachyzoite proliferation, while incubation of host cells with BPQ for
5 h prior to infection had a negative effect on parasite growth
(Fig. 1C).
In order to investigate whether treatment of N. caninum in-
fected HFF with BPQ had parasiticidal effects or acted only
parasitostatically, infected HFF were exposed to different concen-
trations of BPQ for 3–9 days as indicated in Table 1. At deﬁned time
points, the drug pressure was released and cultures were main-
tained in medium without BPQ and were inspected daily by light
microscopy for the presence of tachyzoites and tachyzoite prolif-
eration. We found that the continuous presence of 100 nM BPQ in
N. caninum-infected HFF did not exert parasiticidal activity in the
long term, since parasite-induced lysis of host cells started to occur
after 20 days, indicating that tachyzoites could adapt to this con-
centration of BPQ (Table 1). Treatments at 0.5 μM BPQ for 3 and 6
days did also not exert parasiticidal activity, while 9 days were suf-
ﬁciently long to eliminate all viable N. caninum tachyzoites (no
growth observed after 35 days without BPQ). When treatments were
performed at 1 or 2.5 μM BPQ, 6 days were suﬃcient to exert para-
siticidal activity.
3.2. Transmission electron microscopy of BPQ-treated
N. caninum tachyzoites
N. caninum infected HFFwere treatedwith 1 μMBPQ, and samples
were ﬁxed and processed for TEM after 1, 3 and 5 days, respective-
ly. BPQ treatment induced distinct ultrastructural changes in
N. caninum tachyzoites, although surprisingly these changes oc-
curred not immediately but only after several days of drug treatment.
Control specimens ﬁxed at 48 h and not exposed to drug treat-
ment are shown in Fig. 2A and at higher magniﬁcation in Fig. 2B.
Intracellular tachyzoites reside in the cytoplasm of their host cell
within a parasitophorous vacuole (PV), surrounded by a PV mem-
brane. Tachyzoites exhibited typical features such as a posterior
nucleus, anterior apical complex with conoid, micronemes and
rhoptries, and electron-dense granules andmitochondria were clearly
visible. The matrix of the PV is composed of a tubular network. Fre-
quently, tachyzoites undergoing replication by endodyogeny could
be identiﬁed.
Specimens of N. caninum tachyzoites treated with 1 μm BPQ
during 24 h did not exhibit noticeable ultrastructural alterations
(Fig. 2C). On the other hand, slight but distinct changes in parasite
morphology were noticeable in cultures treated for 3 days (Fig. 3A,
B), mostly with regard to an increased formation of cytoplasmic vacu-
oles. However, no alterations that would indicate parasite death, such
as nuclear condensation or severe changes in the parasite cyto-
plasm were noted at this stage. Few parasites exhibited peripheral
accumulation of electron dense material, and in many instances (see
Fig. 3B) the PV was not readily identiﬁable anymore, indicating that
these tachyzoites could be located freely in the cytoplasm rather
than inside a vacuole. After 5 days of BPQ treatment, dramatic al-
terations in tachyzoites as well as their host cells became evident
(Fig. 3C–F): larger vacuoles containing numerous tachyzoites had
disappeared. The majority of parasites that could be identiﬁed were
single tachyzoites, often exhibiting increased vacuolization and
nuclear condensation indicating cell death, and some associatedwith
either electron-dense accumulations at their periphery (Fig. 3C). Al-
ternatively there were visible PVs that appeared either empty or
ﬁlled with less electron-dense material of unknown nature (Fig. 3D).
In addition, many lipid droplets were found in the vicinity of BPQ-
treated parasites. Few tachyzoites (less than 1%) were found
exhibiting a largely intact ultrastructure, at least on the section plane
visualized (see tachyzoitemarkedwith an arrow in Fig. 3D). However,
there was no clearly deﬁned PV delineated by a PVmembrane visible
in most BPQ-treated specimens. In addition, host cells contained
large numbers of PVs, which contained remnants of BPQ-treated
parasites with no discernible ultrastructure, and which were either
surrounded by membrane stacks (Fig. 3E) or single membranes
(Fig. 3D).
3.3. Effects of BPQ treatment in experimentally infected mice
The N. caninum Nc-Liv isolate is highly virulent. Experimental in-
fection in non-drug-treated control mice (receiving corn oil only
Fig. 2. Short-term (up to 24 h) BPQ treatment of N. caninum tachyzoites cultured
in human ﬁbroblasts does not induce structural alterations. (A) Low magniﬁcation
view of a non-treated N. caninum-infected HFF ﬁxed and processed at day 4 p.i. Nu-
merous tachyzoites reside within a parasitophorous vacuole (PV) just adjacent to
the host cell nucleus (hcnu). (B) A higher magniﬁcation view of (A). The PV matrix
is composed of a tubular network (PVtn). The tachyzoite nucleus (nu), mitochondrium
(mito) and secretory organelles such as rhoptries (rho), micronemes (mic) and dense
granules (dg) are easily identiﬁed. The white arrows in A and B point toward a zoite
undergoing endodyogeny. (C) N. caninum tachyzoites that were exposed to 0.5 μM
BPQ for 24 h. No structural alterations were visible, con = conoid. Bar in A = 3.8 μm;
B = 0.9 μm; C = 1.0 μm.
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Fig. 3. Longer-term BPQ treatment (24–120 h) of N. caninum tachyzoites cultured in human ﬁbroblasts alters the ultrastructure of N. caninum tachyzoites. (A and B) Typical
specimens ﬁxed and processed after 72 h of drug treatment. Tachyzoites were found either in large parasitophorous vacuoles (A), or the parasitophorous vacuole was not
discernible (B), and some tachyzoites had developed electron-dense accumulations at their periphery (white arrows in B). In any case, tachyzoites exhibited an increased
cytoplasmic vacuolization (v). hcnu = host cell nucleus, nu = tachyzoite nucleus, rho = rhoptries. Ultrastructural changes were more evident after 120 h of BPQ treatment. In
about 80% of cases parasites were still recognizable, but clearly damaged (C, D), with condensed nucleus (nuc), aberrant cytoplasmic organization with large vacuoles (v).
There is no parasitophorous vacuole visible, but electron dense material accumulating at the tachyzoite periphery (black arrows in C), vacuolization in the host cell cyto-
plasm adjacent to the parasites (vac), and formation of many lipid droplets (ld). (E and F) Examples of completely distorted tachyzoite residues (Tachy), either packed into
a vacuole and surrounded by several membranes (E), or as a single entity delineated by a still intact plasma membrane only (F). Bars in A and B = 1.5 μm, C = 1.7 μm, D = 1.6 μm,
E and F = 0.9 μm.
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either by i.p. injection or orally by gavage) lead to mortality of 10
out of the 12 control animals. On the other hand, BPQ treatment
exhibited a profound protective effect, no matter whether the drug
was applied i.p. or orally, with an overall mortality in only 3 out of
total 13 animals from the two BPQ treated groups (see Table 2). Most
animals that succumbed to infection did so during the acute phase
of disease, meaning between day 6 and 9 p.i. They exhibited symp-
toms such as ruﬄed coat, rounded back and apathy, reaching a
clinical score that required euthanasia. The only exception was one
mouse in the group receiving oral BPQ treatment, which was eu-
thanized at day 19 p.i. due to hind limb paralysis and circular
movements, indicating neuronal impairment.
Survival analysis was done via Kaplan–Meier estimator (Fig. 4)
followed by regression analysis according to Cox and by Log-Rank
analysis. For i.p. treated mice, both Cox and Log-Rank-tests gave P
values <0.05. For orally treatedmice, the P values were slightly higher,
but below 0.1. Since the survival curves of orally and i.p. treatedmice
showed the same tendencies, both applications could be com-
bined. In this case, the survival analysis gave P values <0.02 for both
tests. BPQ prevented neosporosis symptoms in 4 out of 6 mice in
the i.p. treated group, and in 6 out of 7 mice in the group receiv-
ing oral treatment. In the corresponding control groups, all 6 mice
injected i.p. with corn oil alone died of acute neosporosis, but only
4 out of 6 mice died in the orally treated control group. This indi-
cates that i.p. application is somewhat more incriminating than oral
application, which is not surprising as it represents an invasive
procedure.
Analysis of the parasite load in the brain and in the lungs was
performed by quantitative PCR. Parasite loads in the lungs were sig-
niﬁcantly lower (2-way-ANOVA followed by pairwise t-tests with
Bonferroni correction) in the two BPQ-treated groups compared to
the corresponding control groups (Fig. 5A). On the other hand, the
infection intensity in the brain was higher in the BPQ-treated groups
compared to the cerebral parasite load in the controls. This effect
was more pronounced in the orally treated animals (Fig. 5B).
4. Discussion
BPQ, currently known as the only active drug against theilerio-
sis, is also highly active against N. caninum in vitro. In short term
(4-day) proliferation assays, BPQ was active with an IC50 of 4.9 nM,
which is one of the lowest values reported so far for drugs that were
assessed againstN. caninum in vitro. The IC50 formiltefosinewas 5 μM
(Debache and Hemphill, 2012), and two dicationic compounds (the
arylimidamides DB745 and DB750) inhibited N. caninum prolifer-
ation in vitro with IC50s of 80–160 nM (Debache et al., 2011; Schorer
et al., 2012). More recently, the bumped kinase inhibitor (BKI) 1294,
which is targeted against the calcium dependent protein kinase 1
(CDPK1), was shown to inhibit N. caninum in vitro proliferation with
an IC50 of 30 nM (Ojo et al., 2014). For all three compound groups,
in vivo treatments in experimentally infectedmice resulted in various
beneﬁcial effects such as reduced mortality and lower cerebral par-
asite burdens. Recently, 2 organometallic ruthenium compounds
were reported to exhibit similarly low IC50 values of 6–12 nM (Barna
et al., 2013), but they have not been assessed in vivo. For most other
compounds that were reported to act against N. caninum in vitro and
in vivo, such as artemisone (Mazuz et al., 2012) and ponazuril (Darius
et al., 2004), no IC50 values have been reported.
Inhibition of N. caninum tachyzoite proliferation occurred even
as BPQ was added after 72 h p.i., but conversely, extracellular
tachyzoites were not affected by this compound. Prophylactic treat-
ment of HFF monolayers for one hour, followed by infection with
N. caninum tachyzoites and culture in the absence of BPQ, did not
affect these parasites, but pre-treatment for 5 h reduced intracel-
lular proliferation by 80% compared to controls. This indicates that
BPQ, due to its lipophilic nature, was not taken up eﬃciently by HFF
in the short term (1 h), but after 5 h the compound has reached the
intracellular space of HFF monolayers, and then exerted its activ-
ity and inhibited tachyzoite proliferation. In any case, these results
Fig. 4. Mice infected with N. caninum and subsequently treated with buparvaquone
(PBQ) have a higher survival rate than control mice. Survival ratio of the mice as
listed in Table 2 expressed as Kaplan–Meier-Estimator (KME); or = oral application
of buparvaquone (BPQ) or solvent (control); i.p. = intraperitoneal application.
Fig. 5. Mice treated with buparvaquone (BPQ) have a lower parasite load in lungs,
but not in brains. Balbc mice were infected with Nc-Liv tachyzoites and subse-
quently treated with buparvaquone or solvent as detailed in Table 2. After euthanasia,
lungs and brains were collected and the amount of tachyzoites was determined by
quantitative PCR. (A) Boxplots of tachyzoites in lungs; (B) boxplots of tachyzoites
in brains. Values superscribed by different letters are signiﬁcantly different (P < 0.05;
two-way-ANOVA followed by pairwise-t-tests with Bonferroni correction).
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show that the eﬃcacy of BPQ was exerted only upon intracellular
parasites, this in contrast to what has been observed for other com-
pounds such as DB745 (Schorer et al., 2012) and ruthenium based
organometallic drugs (Barna et al., 2013). On the other hand, the
BKI 1294 clearly inhibited host cell invasion and did not affect in-
tracellular tachyzoite replication. However, as shown by electron
microscopy, the BKI 1294 interfered in the formation of daughter
zoites during endodyogeny, resulting in large multinucleated com-
plexes that were trapped within the host cells and eventually died
(Ojo et al., 2014).
Despite its low IC50 value, BPQ treatment did not clear an infec-
tion in vitro immediately. On the contrary, at 100 nM BPQ, a
concentration that inhibited the parasite replication in 4-day assay
by 100%, long-term treatments (up to 20 days) gave rise toN. caninum
tachyzoites that had obviously adapted to BPQ, and this resulted in
recurrence of parasite replication. As reported earlier, N. caninum
tachyzoites also adapted readily to other experimental com-
pounds such as pentamidine derivatives (Schorer et al., 2012)
(Schorer et al., 2012) and ruthenium-based drugs (Barna et al., 2013),
with the ability to resume proliferation at concentrations that were
up to 20 times higher than the corresponding IC50s of non-adapted
parasites. Similar ﬁndings were obtained for T. gondii tachyzoites
(Kropf et al., 2012). How this drug adaptation in N. caninum is
achieved has not been investigated so far. However, adaptation could
be accompanied by an increased expression of genes coding for com-
ponents of the detoxiﬁcation machinery, such as e.g. ATP-binding
cassette (ABC) transporters, which represent an important family
of membrane proteins such as P-glycoprotein involved in drug re-
sistance and other biological activities in the closely related
Toxoplasma (Schmid et al., 2009), and might also be relevant in
Neospora. Another potential adaptation mechanism could involve
the reduced uptake of drugs, due to the downregulation of trans-
porter activities (such as the adenosine transporters which are
involved in diamidine uptake in trypanosomes (Matovu et al., 2003;
Witola et al., 2004)). Down regulation of the expression of such trans-
porters could, besides limiting drug uptake, also limit the uptake
of other, potentially essential molecules, and this could contribute
to the initially reduced proliferation. It is not known whether the
ability to drug adaptation also occurs in vivo. However, the fact that
N. caninum has an outstanding adaptive potential to cell culture
changes even in the absence of drugs has been noted by others earlier
(Perez-Zaballos et al., 2005).
Only after prolonged treatments at concentrations in the mi-
cromolar range – thus three orders of magnitude above the IC50 –
a complete parasite clearance could be observed in vitro. This can
be explained by the fact that a small number of tachyzoites re-
mained fully intact after BPQ treatment. Upon early release of drug
pressure, these would be the tachyzoites to restart proliferation. At
thismomentwe cannot saywhether these parasites represent a stage
that resembles the classical cyst-forming bradyzoites, as this would
require studies on expression of bradyzoite-speciﬁc genes such as
BAG1 (Vonlaufen et al., 2002), SAG4 (Fernandez-Garcia et al., 2006),
or BSR4 (Risco-Castillo et al., 2007). However, TEM observations did
not indicate that the formation of a cyst wall, or cyst wall-like struc-
ture, was initiated during BPQ treatments, as previously observed
for sodium nitroprusside treated N. caninum-infected keratinocytes
and Vero cell cultures (Vonlaufen et al., 2002, 2004).
When applied in mice, BPQ showed a beneﬁcial effect in pre-
venting acute neosporosis. The Nc-Liv isolate is highly virulent,
known to establish a rapid systemic infection, which can be visu-
alized by parasite loads in a number of organs such as lungs, kidney,
spleen and liver (Alaeddine et al., 2005) and is responsible for early
death of infected animals shortly after infection (Collantes-Fernandez
et al., 2006). In our experiment, the low parasite burden of BPQ
treated mice in the lungs correlates well with the survival rate. Con-
versely, the cerebral parasite burden in brain tissues was increased
in BPQ treated mice that exhibited a much longer survival time.
However, it is important to note that high parasite loads in the lungs
were measured in animals that mostly died already at days 6–8 p.i.
Earlier studies have shown that at later time points, e.g. in animal
surviving 3–4weeks, parasite loads in lungs are signiﬁcantly reduced,
even in the absence of drug treatment (Alaeddine et al., 2005;
Collantes-Fernandez et al., 2006).
Thus, it is conceivable that (i) the start of BPQ treatment at 48 h
p.i. did not eliminate 100% of tachyzoites, with some parasites re-
maining viable and still infective (similar to the in vitro situation;
see above); (ii) as a consequence BPQ did not completely prevent
tachyzoites from crossing the blood–brain border since parasites
already had 48 h prior to treatment to reach the CNS; and (iii) with
the brain representing an immune-privileged site even low numbers
of parasites establishing a cerebral infection underwent prolifera-
tion without causing extensive immunopathology. Thus, the
treatment with BPQ early after inoculation of N. caninum tachyzoites
could potentially be a suitable method to establish an infection in
mice that is localized exclusively in the brain. Upon release of the
drug pressure and subsequent pregnancy, this infection could become
systemic and then be vertically transmitted to the offspring, thus
mimicking the situation in cattle. This may constitute a suitable tool
for studies on the biology of cerebral Neospora infection and/or
control options (including vaccination) that aim to prevent endog-
enous transplacental N. caninum infection in chronically infected
animals, for which a good and reliable mouse model is not yet avail-
able despite considerable efforts that have been undertaken
(Jiménez-Ruiz et al., 2013).
The in vivo experiments show that BPQ applied as a suspen-
sion in corn oil inhibited the outbreak of acute neosporosis in
N. caninum infectedmice, but further studies are required to improve
eﬃcacy. BPQ has a low aqueous solubility and high lipophilicity,
properties that hamper absorption. One option could be to employ
the more hydrophilic BPQ-3-phosphate as a prodrug, which was su-
perior to BPQ in reducing the liver parasite burden in Leishmania
donovani-infected mice, and to employ other vehicles such as
isopropyl-myristate and polyethylene-glycol 400 (Garnier et al.,
2007), which could increase solubility and bioavailability. In addi-
tion, novel oxime derivatives of BPQ and O-methyl-BPQ were
evaluated in vitro against L. donovani, and showed promising ac-
tivities, thus they could also provide valuable alternatives. However,
there are no reports on in vivo activity of these compounds (Mäntylä
et al., 2004). Another possibility includes application of a recently
developed formulation that contains BPQ coupled to solid lipid par-
ticles. Studies in rats demonstrated an altered biodistribution and
pharmacokinetics of the drug, and an increased half-life of up to
20 h (Soni et al., 2014). In addition, one should take into account
to combine BPQ with other compounds that eﬃciently cross the
blood–brain barrier and limit cerebral infection, such as the pre-
viously studied calcium dependent kinase inhibitor 1294 (Ojo et al.,
2014). These compounds could act synergistically and clear both
acute disease as well as CNS invasion.
In conclusion, we have demonstrated the in vitro characteris-
tics of BPQ activities in N. caninum tachyzoites, and shown that
application of this compound in mice prevents acute neosporosis,
but the compound does apparently not cross the blood–brain barrier
in suﬃcient amounts to kill the parasites in the CNS. However, further
investigations will show whether this drug is capable of prevent-
ing infection of the fetus in pregnant mice. Pharmacokinetic studies
of BPQ in cattle have shown that the maximum concentration in
blood plasma of a marketed BPQ formulation (Butalex™) injected
intramuscularly was around 0.229 μg/ml, corresponding to 700 nM,
and a mean time to reach this concentration was 2.6 h (Muraguri
et al., 2006). Whether these properties are suﬃcient to prevent
N. caninum recrudescence in pregnant animals and to protect the
fetus from infection remains to be investigated.
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